Zobrazeno 1 - 10
of 368
pro vyhledávání: '"Preclinical AD"'
Autor:
Silvia Paciotti, Anna Lidia Wojdała, Giovanni Bellomo, Andrea Toja, Elena Chipi, Sander R. Piersma, Thang V. Pham, Lorenzo Gaetani, Connie R. Jimenez, Lucilla Parnetti, Davide Chiasserini
Publikováno v:
Alzheimer’s Research & Therapy, Vol 15, Iss 1, Pp 1-12 (2023)
Abstract Background Alzheimer’s disease (AD) cerebrospinal fluid (CSF) core biomarkers (Aβ42/40 ratio, p-tau, and t-tau) provide high diagnostic accuracy, even at the earliest stage of disease. However, these markers do not fully reflect the compl
Externí odkaz:
https://doaj.org/article/8734a334353f401e8bf8593ff2eaad52
Autor:
Aliaa Ibnidris, Janelle N. Robinson, Marissa Stubbs, Giovanni Piumatti, Ishtar Govia, Emiliano Albanese
Publikováno v:
Systematic Reviews, Vol 11, Iss 1, Pp 1-17 (2022)
Abstract Background Subjective cognitive decline (SCD) is present in the early stage of preclinical Alzheimer’s disease (AD) and is associated with an increased risk of further cognitive decline and AD dementia later in life. Early detection of at-
Externí odkaz:
https://doaj.org/article/f0ab3c7da154408e95acf507e99644cd
Publikováno v:
Frontiers in Medicine, Vol 10 (2023)
Worldwide, approximately 22% of all individuals aged 50 years and older are currently estimated to fall somewhere on the Alzheimer’s disease (AD) continuum, which can be roughly divided into preclinical AD, mild cognitive impairment (MCI), and AD d
Externí odkaz:
https://doaj.org/article/d0bb0b588c2145ea822cc7483b02f3e2
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Tao-Ran Li, Yun-Xia Yao, Xue-Yan Jiang, Qiu-Yue Dong, Xian-Feng Yu, Ting Wang, Yan-Ning Cai, Ying Han
Publikováno v:
Alzheimer’s Research & Therapy, Vol 14, Iss 1, Pp 1-13 (2022)
Abstract Background Blood biomarkers that can be used for preclinical Alzheimer’s disease (AD) diagnosis would enable trial enrollment at a time when the disease is potentially reversible. Here, we investigated plasma neuronal-derived extracellular
Externí odkaz:
https://doaj.org/article/744b446c196f4ababa7cd0da720cc870
Publikováno v:
Disease Models & Mechanisms, Vol 16, Iss 3 (2023)
Externí odkaz:
https://doaj.org/article/561b453b1f4c4436a48d6c5c83fc0718
Autor:
Byron Creese, Zahinoor Ismail
Publikováno v:
Alzheimer’s Research & Therapy, Vol 14, Iss 1, Pp 1-5 (2022)
Abstract Background Late-life onset neuropsychiatric symptoms are established risk factors for dementia. The mild behavioral impairment (MBI) diagnostic framework was designed to standardize assessment to determine dementia risk better. In this Mini
Externí odkaz:
https://doaj.org/article/5329f968756148668abbf0d34d02292c
Publikováno v:
Frontiers in Psychiatry, Vol 13 (2022)
Neuropsychiatric symptoms (NPS) occur in nearly all patients with Alzheimer's Disease (AD). Most frequently they appear since the mild cognitive impairment (MCI) stage preceding clinical AD, and have a prognostic importance. Unfortunately, these symp
Externí odkaz:
https://doaj.org/article/06b5d9be81374fa09dd7299b9437f406
Publikováno v:
Alzheimer’s Research & Therapy, Vol 13, Iss 1, Pp 1-11 (2021)
Abstract Background In the current study, we aimed to develop an algorithm based on biomarkers obtained through non- or minimally invasive procedures to identify healthy elderly subjects who have an increased risk of abnormal cerebrospinal fluid (CSF
Externí odkaz:
https://doaj.org/article/a7689931f0644552b7feafa5d357d2b7